leadforensics

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Find out more about cookies.

Click here to dismiss this banner

PHARMA REPORT

rss_Pharma.jpg...see all
Endometriosis Drug Forecasts and R&D 2017-2027

Endometriosis Drug Forecasts and R&D 2017-2027

Forecasts and Analysis of Leading Endometriosis Drugs (Lupron, Eligard, Zoladex, Depo-Provera, Visanne), Companies and Key National Markets

Product code: PHA0221

  • Publication date: 07/08/2017
  • Number of Pages: 146
  1. Report Details
  2. Table of Contents
  3. Companies Listed

Report Details

Endometriosis – our new study reveals trends, R&D progress, and predicted revenues
Where is the Endometriosis market heading? If you are involved in this sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead
Our 146-page report provides 108 tables, charts, clearly illustrating the data presented in this research. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted drug sales at overall world market regional level, as well as giving a deep insight into the pipeline for Endometriosis. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Endometriosis market. See how to exploit the opportunities.

Forecasts to 2027 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2027, our new study provides you with recent results, R&D overview, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the world market and following Endometriosis Therapeutics:
• Lupron
• Eligard
• Zoladex
• Depo-Provera
• Visanne

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 11 leading national markets:
• The US
• Germany
• France
• The UK
• Spain
• Italy
• Japan
• China
• India
• Brazil
• Russia
• RoW

Endometriosis Drug Forecasts and R&D 2017-2027

The report also includes profiles and pipeline analysis for some of the leading companies in the Endometriosis market, with a focus on the Endometriosis segment of these companies’ operations.

There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, Germany, France and India in particular, will continue to achieve high revenue growth to 2027.

Leading companies and the potential for market growth
Overall world revenue for Endometriosis will surpass $3bn in 2027, our work calculates. This will be driven by the development of more effective drugs for the condition as well as raising awareness of Endometriosis over the forecast period

Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Endometriosis Market report helps you
In summary, our 146-page report provides you with the following knowledge:
• Revenue forecasts to 2027 for the Endometriosis market and 5 Leading Therapeutic Drugs for the condition – discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2027 for 11 of the leading national markets – US, Germany, France, UK, Italy, Spain, Russia, Japan, China, India, Brazil
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market – including company profiles and R&D overviews for 10 companies involved in developing and manufacturing Endometriosis drugs

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the Endometriosis market and leading companies. You will find data, trends and predictions.

Get our report today Endometriosis Drug Forecasts and R&D 2017-2027: Forecasts and Analysis of Leading Endometriosis Drugs (Lupron, Eligard, Zoladex, Depo-Provera, Visanne), Companies and Key National Markets. Avoid missing out – get our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Table of Contents

1. Report Overview
1.1. Endometriosis Drugs: Industry and Market Review
1.2. Benefits of This Report
1.3. How This Study Delivers
1.4. Main Questions This Work Answers
1.5. Who is This Report For?
1.6. Methods of Research and Analysis
1.7. Frequently Asked Questions (FAQ)
1.8. Some Related Visiongain Reports
1.9. About Visiongain

2. Introduction to Endometriosis and its Treatment
2.1. What is Endometriosis?
2.2. Incidence and Prevalence of Endometriosis
2.3. The Endometriosis Drug Market, 2016
2.4. PEST Analysis
2.4.1. Political Factors
2.4.2 Economic Factors
2.4.3 Social Factors Affecting the Endometriosis Therapies Market
2.4.4 Technological Developments in Endometriosis Treatment
2.5 Market Growth Drivers and Restraints
2.6 Outlook for the Endometriosis Drugs Market, 2016-2027

3. Leading National Markets: Outlooks, 2017-2027
3.1 Endometriosis Treatment by Therapy
3.1.1. Hormones
3.1.2. Painkillers
3.1.3. Surgical Treatment

4. Endometriosis Leading National Markets, 2017-2027
4.1. Leading National Markets: The US Dominated in 2016
4.1.1. What is The Future for Leading National Markets?
4.2. The US Endometriosis Market, 2017 to 2027
4.3. EU5 Endometriosis Market, 2017 to 2027
4.3.1. The UK Endometriosis Market, 2017 to 2027
4.3.2. French Endometriosis Market, 2017 to 2027: Steady Growth throughout the Forecast Period
4.3.3. German Endometriosis Market, 2017 to 2027: Largest Market Share in European Union
4.3.4. Spanish Endometriosis Market, 2017 to 2027
4.3.5. Italian Endometriosis Market, 2017 to 2027
4.4. Japanese Endometriosis Market, 2017 to 2027: Second Largest Market in the World
4.5. Chinese Endometriosis Market, 2017 to 2027
4.6. Indian Endometriosis Market, 2017 to 2027: Fast Growing Market
4.7. Brazilian Endometriosis Market, 2017 to 2027
4.8. Russian Endometriosis Market, 2017 to 2027

5. Leading Drugs in World Endometriosis Market, 2016
5.1. Lupron: One of the Leading Endometriosis Drug in the Market
5.1.1. Profile
5.1.2. Lupron Historical Revenue
5.1.3. Lupron Revenue Forecast, 2017-2027
5.2. Eligard: Facing Challenges When Patent Expires
5.2.1. Profile
5.2.2. Eligard Historical Revenue
5.2.3. Eligard Revenue Forecast, 2017-2027
5.3. Zoladex
5.3.1. Profile
5.3.2. Zoladex Historical Revenue
5.3.3. Zoladex Revenue Forecast, 2017-2027
5.4. Depo-Provera
5.4.1. Profile
5.4.2. Depo-Provera Historical Revenue
5.4.3. Depo-Provera Forecast, 2017 to 2027
5.5. Visanne: First Oral Treatment for Endometriosis by Bayer
5.5.1. Profile
5.5.2. Visanne Historical Revenue
5.5.3. Visanne Forecast, 2017 to 2027

6. Research and Development for Endometriosis Drugs
6.1. Industry Collaboration and R&D Activities
6.1.1. Investigational Drug Treatment for Endometriosis
6.2. Companies Involved in Producing Drugs for Endometriosis
6.3. AbbVie: Leading Producer of Endometriosis Drugs
6.3.1. Company Description
6.3.2. Business Segmentation
6.3.3. AbbVie Revenue Performance, 2016
6.3.4. Product in Pipeline: Elagolix, Oral Drug
6.4. Pfizer
6.4.1. Company Description
6.4.2. Business Segmentation
6.4.3. Pfizer Revenue Performance, 2016
6.5. Bayer HealthCare: Visanne Showing Faster Growth in Revenue
6.5.1. Company Description
6.5.2. Business Segmentation
6.5.3. Bayer HealthCare Revenue Performance, 2016
6.5.4. Four Drug Candidates in Product Pipeline
6.6. AstraZeneca
6.6.1. Company Description
6.6.2. Business Segmentation
6.6.3. AstraZeneca Revenue Performance, 2016
6.7. Astellas
6.7.1. Company Description
6.7.2. Business Segmentation
6.7.3. ASP1707 an Oral Dosage Form: Product in Pipeline
6.8. Takeda
6.8.1. Company Description
6.8.2. Business Segmentation
6.8.3. Product in Pipeline: Relugolix- Oral Form
6.9. Repros Therapeutics Inc.
6.9.1. Company Description
6.9.2. Business Segmentation
6.9.3. Product in Pipeline: Proellex in Phase II Trials
6.10. Euroscreen S.A.
6.10.1. Company Description
6.10.2. Business Segmentation
6.10.3. Product in Pipeline: ESN364 Completes Enrolment in Phase II Trials
6.11. Kissei Pharmaceutical
6.11.1. Company Description
6.11.2. Business Segmentation
6.11.3. Product in Pipeline: KLH-2109 Exclusive Rights Given to ObsEva
6.12. Addex Therapeutics
6.12.1. Company Description
6.12.2. Product in Pipeline

7. Qualitative Analysis of Endometriosis Drugs Market
7.1. SWOT Analysis: Future Scope of The Market
7.2. Strengths of The Market
7.2.1. Vast, Expanding Ageing Population
7.2.2. A Number of Promising Drug Candidates
7.2.3. Secondary Indications
7.3. Weaknesses
7.3.1. Lack of Disease Awareness
7.3.2. Reimbursement Issues
7.3.3. Demand for Better Diagnosis and Treatment of Endometriosis
7.4. Opportunities
7.4.1. Rising Disease Prevalence
7.4.2. Increased Demand in Market
7.4.3. Novel Mechanisms and Delivery Methods
7.5. Threats
7.5.1. Competition from Generic Drugs
7.5.2. Governments Limiting Healthcare Spending

8. Conclusions from the Research and Analysis
8.1. Future of the Endometriosis Pharmaceuticals Market
8.2. The US Will Remain The Largest National Market From 2017 to 2027
8.3. Trends in the Endometriosis Treatments Market

9. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain Report Evaluation Form

List of Figures in this Report
Figure 2.1 Prevalence of Endometriosis in Women (in Millions), Leading Countries, 2016
Figure 2.2 Global Endometriosis Market Revenue Performance: Revenue ($bn), 2014-2016
Figure 2.3 Global Endometriosis Market: Drivers and Restraints, 2017-2027
Figure 2.4 Forecast Global Endometriosis Market: Revenue ($m), 2016-2027
Figure 4.1 Endometriosis Leading National Markets: Shares (%), 2016
Figure 4.2 Endometriosis Leading National Markets: Shares (%), 2016
Figure 4.3 Endometriosis Leading National Markets: Shares (%), 2022
Figure 4.4 Endometriosis Leading National Markets: Shares (%), 2027
Figure 4.5 The US Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.6 EU5 Endometriosis Therapeutic Market: Overall Revenue ($m), 2016-2027
Figure 4.7 EU5 Endometriosis Therapeutic Markets: National Shares (%), 2016, 2022 and 2027
Figure 4.8 EU5 Endometriosis Therapeutic Market Forecast: Revenue ($m) Breakdown by Countries, 2016-2027
Figure 4.9 The UK Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.10 French Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.11 German Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.12 Spanish Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.13 Italian Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.14 Japanese Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.15 Chinese Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.16 Indian Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.17 Brazilian Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.18 Russian Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.1 Endometriosis Drug Market: Revenue ($m) by Leading Drug, 2016
Figure 5.2 Endometriosis Drug Market: Revenue Share (%) by Leading Drugs, 2016
Figure 5.3 Endometriosis Drug Market: Revenue Share (%) by Leading Drugs, 2022
Figure 5.4 Endometriosis Drug Market: Revenue Share (%) by Leading Drugs, 2027
Figure 5.5 Lupron Revenue Segmentation: Revenue Share (%), 2016
Figure 5.6 Lupron Historical Revenue ($m), 2011-2016
Figure 5.7 Lupron Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.8 Eligard Revenue Segmentation: Revenue Share (%), 2016
Figure 5.9 Eligard Historical Revenue ($m), 2011-2016
Figure 5.10 Eligard Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.11 Zoladex Revenue Segmentation: Revenue Share (%), 2016
Figure 5.12 Zoladex Historical Revenue ($m), 2011-2016
Figure 5.13 Zoladex Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.14 Depo-Provera Revenue Segmentation: Revenue Share (%), 2016
Figure 5.15 Depo-Provera Historical Revenue ($m), 2011-2016
Figure 5.16 Depo-Provera Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.17 Visanne Historical Revenue ($m), 2011-2016
Figure 5.18 Visanne Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 6.1 AbbVie: Therapeutic Focus Areas, 2016
Figure 6.2 AbbVie: Revenue Share (%) for Lupron, 2016
Figure 6.3 Pfizer: Revenue ($m) by Business Segment, 2016
Figure 6.4 Pfizer: Revenue Share (%) by Business Segment, 2016
Figure 6.5 Bayer: Revenue Share (%) by Drugs, 2016
Figure 6.6 Bayer: Revenue Share ($m) by Drugs, 2016
Figure 6.7 AstraZeneca: Revenue ($m) by Segment, 2016
Figure 6.8 AstraZeneca: Revenue Share of Drugs (%), 2016
Figure 6.9 AstraZeneca: Revenue ($m) by Drugs, 2016

List of Tables in this Report
Table 1.1 Endometriosis Drug Sales: Leading National Markets, Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 1.2 Foreign Currency Exchange Rate to $US, 2016
Table 2.1 Prevalence of Endometriosis in Women: Leading Countries, 2016
Table 2.2 Global Endometriosis Market Revenue Performance: Revenue ($bn) and AGR (%), 2014-2016
Table 2.3 Political, Economic, Social and Technological Forces (PEST) Affecting Endometriosis Market, 2016
Table 2.4 Global Endometriosis Market: Revenues ($m), Annual Growth Rate (%), CAGR (%), 2016-2022
Table 2.5 Global Endometriosis Market: Revenues ($m), Annual Growth Rate (%), CAGR (%), 2022-2027
Table 4.1 Endometriosis Leading National Markets: Revenue ($m) and Market Share (%), 2016
Table 4.2 Endometriosis Leading National Markets Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.3 Market Share (%) and Revenue ($m) Comparison of the Leading Endometriosis Therapeutic National Markets, 2016, 2022 and 2027
Table 4.4 The US Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022
Table 4.5 The US Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027
Table 4.6 EU5 Endometriosis Therapeutic Market Forecasts by Country: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 4.7 The UK Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022
Table 4.8 The UK Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027
Table 4.9 Historical and Future Profile of Payment Percentages
Table 4.10 French Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022
Table 4.11 French Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027
Table 4.12 German Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022
Table 4.13 German Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027
Table 4.14 Spanish Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022
Table 4.14 Spanish Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027
Table 4.16 Italian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022
Table 4.17 Italian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027
Table 4.18 Japanese Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022
Table 4.19 Japanese Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027
Table 4.20 Chinese Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022
Table 4.21 Chinese Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027
Table 4.22 Indian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022
Table 4.23 Indian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027
Table 4.24 Brazilian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022
Table 4.25 Brazilian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027
Table 4.26 Russian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022
Table 4.27 Russian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027
Table 5.1 The Endometriosis Drug Market: Revenue ($m), Revenue Share (%) by Leading Drugs, 2016, 2022, 2027
Table 5.2 Endometriosis Market: Forecasts by Leading Drugs, Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 5.3 Lupron Revenue Segmentation: Revenue ($m), Revenue Share (%), 2016
Table 5.4 Lupron Historical Revenue ($m), Annual Growth (%) and CAGR (%), 2011-2016
Table 5.5 Lupron Forecast: Revenue ($m), Annual Growth (%) and CAGR (%), 2016-2027
Table 5.6 Eligard Revenue Segmentation: Revenue ($m), Revenue Share (%), 2016
Table 5.7 Eligard Historical Revenue ($m), Annual Growth (%) and CAGR (%), 2011-2016
Table 5.8 Eligard Forecast: Revenue ($m), Annual Growth (%) and CAGR (%), 2016-2027
Table 5.9 Zoladex Revenue Segmentation: Revenue ($m), Revenue Share (%), 2016
Table 5.10 Zoladex Historical Revenue ($m), Annual Growth (%) and CAGR (%), 2011-2016
Table 5.11 Zoladex Forecast: Revenue ($m), Annual Growth (%) and CAGR (%), 2016-2027
Table 5.12 Depo-Provera Revenue Segmentation: Revenue ($m), Revenue Share (%), 2016
Table 5.13 Depo-Provera Historical Revenue ($m), Annual Growth (%) and CAGR (%), 2011-2016
Table 5.14 Depo-Provera Forecast: Revenue ($m), Annual Growth (%) and CAGR (%), 2016-2027
Table 5.15 Visanne Historical Revenue ($m), Annual Growth (%) and CAGR (%), 2011-2016
Table 5.16 Visanne Forecast: Revenue ($m), Annual Growth (%) and CAGR (%), 2016-2027
Table 6.1 AbbVie: Drug Revenue ($m) and Change (%), 2015 and 2016
Table 6.2 AbbVie: Drug Revenue ($m) and Drug Revenue Share (%), 2016
Table 6.3 Pfizer: Revenue ($m) and Revenue Share (%) Based on Business Segment, 2016
Table 6.4 Bayer: Revenue ($m) and Revenue Share (%) Based on Business Segment, 2016
Table 6.5 Bayer: Drug Revenue ($m) and Drug Revenue Share (%), 2016
Table 6.6 AstraZeneca: Revenue ($m) and Revenue Share (%) Based on Business Segments, 2016
Table 6.7 List of Other Companies in the Endometriosis Market

Companies Listed

Abbott Laboratories
AbbVie
Ablynx NV
AC Immune SA
Active Biotech AB
Addex Therapeutics Ltd.
Advanced Biological Laboratories SA
AEterna Zenaris
Agenus Schweiz AG
Agios Pharmaceuticals, Inc.
Aileron Therapeutics, Inc.
Akari Therapeutics Plc
Allergan Plc
Amanouchi Pharmaceutical Co.
Amgen, Inc.
Anacor Pharmaceuticals, Inc.
AP Avadis Biotechnologies
Apeiron Biologics Ag
Apogenix GmbH
Aquinox Pharmaceuticals, Inc.
ArQule, Inc.
Array BioPharma, Inc.
Astellas Pharma
AstraZeneca Plc
Atrix Laboratories
Bayer HealthCare
BeiGene Ltd.
BioAtla LLC
Biogen, Inc.
BioNTech AG
BioPorto A/S
Bio-Rad Laboratories, Inc.
Celgene Corp.
Celmatix Inc.
CEL-SCI Corp.
Cepheid
Cidara Therapeutics, Inc.
Cogstate Ltd.
Collplant Holdings Ltd.
CRISPR Therapeutics AG
CTI BioPharma Corp.
Cyprotex Plc
CytomX Therapeutics, Inc.
Debiopharm International Sa
DelsiTech Ltd.
Domain Therapeutics SA
Dongkook Pharmaceutical Co.
ElexoPharm GmbH
Eli Lilly
Enanta Pharmaceuticals, Inc.
EndoCeutics
Epizyme, Inc.
Euroscreen S.A.
Euthymics Bioscience Inc.
Evotec AG
Florida Hospital
Fujisawa Pharmaceutical Co.
Genentech, Inc.
Genzyme Corporation
GlaxoSmithKline
Halozyme Therapeutics, Inc.
HemoShear Therapeutics LLC
Highland Clinical Research
Hydra Biosciences Inc.
Idera Pharmaceuticals, Inc.
ImmunoGen, Inc.
Immunomedics, Inc.
Inc. Forendo Pharma Oy
Infinity Pharmaceuticals, Inc.
Interleukin Genetics, Inc.
Invivo Therapeutics Holdings Corp.
Isifer AB
Jiangsu Kanion Pharmaceutical Co.
Kissei Pharmaceutical
Lipicard Technologies Limited
Medigene AG
Meditrina Pharmaceuticals
Medivation, Inc.
Mendel Biotechnology Inc.
MorphoSys AG
Mylan NV
Myovant Sciences Ltd.
Neurocrine Biosciences, Inc.
NextCure Inc.
ObsEva
OncoMed Pharmaceuticals, Inc.
OncoTherapy Science, Inc.
OPKO Health, Inc.
Orphagen Pharmaceuticals
Peptidream Inc.
Pfizer
Philogen
Philogen Spa
Portola Pharmaceuticals, Inc.
PregLem SA
Probiodrug AG
pSivida Corp.
Puma Biotechnology, Inc.
Repros Therapeutics Inc.
Roche
Sanofi
Schering AG
SK Chemicals Co.
Takeda Pharmaceutical
Tolmar Therapeutics
ValiRX

Organisations Mentioned in This Report
Aljazeera Hospital
Australian National University
Brigham and Women’s Hospital
Centre for Endocrinology and Reproductive Medicine
Centre for Epidemiology and Health Research
Children’s Hospital Boston
Food and Drug Administration (FDA)
Highland Clinical Research
Indian Brand Equity Foundation
Instituto de Investigacion Sanitaria La Fe
Jacksonville Centre for Clinical Research
Jiangsu Kanion Pharmaceutical Co.
Ministry of Health, Labour, and Welfare (Japan)
National Health Service
National Institute for Clinical Excellence
National Institute of Health
Northwestern University
Northwestern University (Illinois)
Research OutSmarts Endometriosis
Turku University Hospital
University Hospital (Angers)
University Hospital (Mo)
University Hospital (Mo)
University Hospital (Rouen)
University of Arhus (Denmark)
University of Athens (Greece)
University of Cagliari (Italy)
University of Illinois
University of North Carolina School of Medicine (North Carolina)
University of Oxford
Women’s Health Care at Frost Street
World Endometriosis Research Foundation

You have successfully subscribed. Thank you.

An internal error has occurred. Please try again later.

close